Clinical pharmacy

1	Course name		С	linical Pharmacy	
2	Course Code			PH402	
				111402	
3	Course type:			general	
	/general/special	lty/optional			
4	Accredited units	3	4 units (3 hrs/week theoretical	
			2 h	rs/week practical)	
5	Educational hou	rs		5 hours/week	
6	Pre-requisite rec	quirements	Ph	armacology 1& 2	
7	Program offered	I the course	Departmei	nt of Pharmaceutical Care	
8	Instruction Lang	uage		English	
9	Date of course a	pproval		12/2021	
Brief	Description:	 The common diseases covering etiology, clinical picture, diagnosis, investigations and therapy 			
for this Course:• Applied T• Pharmac		Applied Th	therapy: A Pathophysic	armacy al Use of Drugs.Marry Anne Koda-Kim ologic approach - Joseph T. Dipiro et a	
Cours	e Duration	28 weeks			
Deliv	Delivery Lecture-based, Gro		oup interaction and dis	scussion, medical clerkshipetc.	
Course Objectives:		 Understand Understand Understand range of Identifie Makes C 	anding the rationale fo acute and chronic con s Drug Therapy Probler linical Decisions throug	ology of selected disease states r drug therapy and the management o ditions.	
		Midyear exam		20%	
		Quizzes, reports, p		10%	
			ous assessment, exam	10%	
		Final Practical exa	m	20%	
		Final theoretical e	xam	40%	
Tot		Total		100%	
Sessio	Session 1 (Week 1) Introduction to the		e Patient Care Process	5:	

	 Definition of clinical pharmacy. Define and understand the role of the patient care process in providing care. 		
	• Describe the components of comprehensive patient history taking.		
	 Apply a process to assess a patient for drug-related problems. 		
	• Outline the components of patients' comprehensive care plans.		
	Develop appropriate documentation of patient care.		
Session 2 (Week 2)	Principles of Patient Assessment		
	• Describe the role of patient assessment in pharmacy practice.		
	Describe the steps of symptoms assessment.		
	Physical Assessment skills for Pharmacists		
	 List available comprehensive guides to physical assessment. 		
Session 3 (Week 3)	Critical Care Assessment:		
	• Describe the role of the pharmacist in the intensive care unit (ICU) and in		
	the care of critically ill patients		
	Describe the steps of critical care assessment, including collecting patient		
	history, assessing the history of present illness, and conducting a review of		
	systems Apply knowledge of routes of administration, intravenous		
	compatibility, and pharmacokinetic.		
	Changes in the critically ill to ensure effective and safe medication delivery		
	to the patient.		
Session 4 (Week 4)	Drug interactions and adverse drug reactions		
Session 5 (Week 5)	Clinical pharmacokinetics and therapeutic drug monitoring of selected drugs		
	(Vancomycin, Aminoglycosides, digoxin, theophylline, carbamazepine)		
Session 6 (Meak 6)	Drug thereasy is enabled non-ulational Programmy Lastation Redictric Conjection		
Session 6 (Week 6)	Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric:		
Session 6 (Week 6)	• Describe the goals of therapy and management strategy for menopause.		
Session 6 (Week 6)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering 		
Session 6 (Week 6)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. 		
Session 6 (Week 6)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women 		
Session 6 (Week 6)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. 		
Session 6 (Week 6) Session 7 (Week 7)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment. 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of 		
Session 7 (Week 7)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of older adults. 		
	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of older adults. Drug management of endocrine disorders: 		
Session 7 (Week 7)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of older adults. Drug management of endocrine disorders: Diabetes Mellitus. 		
Session 7 (Week 7)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of older adults. Drug management of endocrine disorders: Diabetes Mellitus. Describe the diagnostic criteria and tests for diabetes. 		
Session 7 (Week 7)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of older adults. Drug management of endocrine disorders: Diabetes Mellitus. Describe the diagnostic criteria and tests for diabetes. Describe glycemic control targets for different populations with diabetes. 		
Session 7 (Week 7)	 Describe the goals of therapy and management strategy for menopause. Assess women for menopausal symptoms and who may be considering hormone therapy. Describe the goals of therapy and the therapeutic options for women seeking hormonal contraceptives. Assess women who are seeking combined hormonal contraception. Drug therapy in special populations: Pregnancy, Lactation, Pediatric, Geriatric: Recognize challenges related to patient assessment that are unique to pediatrics and neonatology. Describe the required components of a complete pharmacy assessment that are unique to pediatrics and neonatology. Gain a basic understanding of the differences in pediatric assessment as it relates to vital signs and common laboratory parameters Describe the process of comprehensive geriatric assessment. Identify the domains of comprehensive geriatric assessment of older adults. Drug management of endocrine disorders: Diabetes Mellitus. Describe the diagnostic criteria and tests for diabetes. 		

	Describe hyperblacking is a symptome and its tractment, and how to avoid		
	 Describe hypoglycemia, its symptoms and its treatment, and how to avoid it. 		
Session 9 (Week 9)	Drug management of cardiovascular disorders:		
	 Dyslipidemia: Understanding the pathophysiology and it is classifications and Major Risk 		
	Factors		
	 Identify appropriate standards for the diagnosis of dyslipidemia and 		
	determine risk and prognosis for developing cardiovascular disease.		
	Outline the management and treatment lines of hyperlipidemia		
Session 10 (Week 10)	Hypertension:		
	 Understanding approach of assessing a patient with hypertension. To outline the various methods of diagnosis and monitoring for these with 		
	 To outline the various methods of diagnosis and monitoring for those with hypertension. 		
	 To outline appropriate follow-up and monitoring parameters for patients 		
	with hypertension.		
	Complications of Hypertension		
	General Management of hypertension and Special patient groups		
	Resistant hypertension, hypertensive urgencies and emergencies		
Session 11 (Week 11)			
Session 12 (Week 12)	Midyear Exam		
Session 13 (Week 13)			
Session 14 (Week 14)	Least Failure		
Session 15 (Week 15)	Heart Failure: To define heart failure (HF)		
	 To review the diagnosis of HF including common signs and symptoms, risk 		
	factors and common diagnostic tests		
	• To highlight goals of therapy in patients with HF		
	To outline a general approach to a patient with HF including initial		
	assessment and ongoing evaluation and monitoring		
	assessment and ongoing evaluation and monitoringTo provide an approach to pharmacotherapy in HF including parameters		
Session 16 (Mask 16)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. 		
Session 16 (Week 16)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: 		
Session 16 (Week 16)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. 		
Session 16 (Week 16)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: 		
Session 16 (Week 16)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. 		
Session 16 (Week 16)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. 		
Session 16 (Week 16) Session 17 (Week 17)	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: clinical manifestations of venous thromboembolism 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: clinical manifestations of venous thromboembolism pulmonary embolism 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: clinical manifestations of venous thromboembolism pulmonary embolism management of bleeding and excessive anticoagulation 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: clinical manifestations of venous thromboembolism pulmonary embolism 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: clinical manifestations of venous thromboembolism pulmonary embolism management of bleeding and excessive anticoagulation general approach to the treatment 		
	 assessment and ongoing evaluation and monitoring To provide an approach to pharmacotherapy in HF including parameters for initiation and titration of therapy. Coronary heart disease: Pathophysiology of disease. Clinical presentation and diagnosis. Modifiable and non-modifiable Risk factors Clinical syndromes Medical management and prevention Evaluation of therapeutic outcomes. Thrombosis: clinical manifestations of venous thromboembolism pulmonary embolism management of bleeding and excessive anticoagulation general approach to the treatment of venous thromboembolism. treatment of venous 		

Session 18 (Week 18)	Stroke:
503510110 (WCCK 10)	Pathophysiology and classification
	 Etiology and Risk factors.
	 Clinical presentation (including diagnostic considerations.
	 General approach to treatment.
	general information regarding safety and efficacy
	Use available parameters to measure and monitor target lipid goals for
	patients under treatment for dyslipidemia. Review recommendation of
	pivotal clinical trials).
Session 19 (Week 19)	Drug management of respiratory disorders:
	Asthma:
	• Describe the epidemiology, risk factors, clinical presentation and diagnosis
	of asthma.
	 Describe the goals of therapy and management strategies for asthma.
	 Conduct an initial assessment of patients newly diagnosed with asthma.
	Describe the role of inhaled medications and optimal inhalation device use
	in asthma management.
	Conduct a follow-up assessment of patients with asthma.
Session 20 (Week 20)	Chronic Obstructive Pulmonary Disease:
	Non-specific & specific immunity.
	Cells involved in the immune response
	 Types of immunoglobulin & mechanism of antibody production.
	Hypersensitivity reactions.
	Serological tests.
Session 21 (Week 21)	Drug management of neurological disorders:
	Epilepsy:
	• Describe the epidemiology, etiology, risk factors, and pathophysiology of
	 Describe the epidemiology, etiology, risk factors, and pathophysiology of epilepsy.
	epilepsy.
	epilepsy.Describe the classification of different seizure types.
	epilepsy.Describe the classification of different seizure types.Conduct initial assessment of patients newly diagnosed with epilepsy.
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy.
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders:
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression:
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders.
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed.
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using
Session 22 (Week 22)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression.
Session 22 (Week 22) Session 23 (Week 23)	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression.
	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression. Provide guidance to patients on how to manage partial/non-response or adverse effects of medications.
	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression. Provide guidance to patients on how to manage partial/non-response or adverse effects of medications.
	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression. Provide guidance to patients on how to manage partial/non-response or adverse effects of medications. Drug management of bone and joint disorders:
	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression. Provide guidance to patients on how to manage partial/non-response or adverse effects of medications. Drug management of bone and joint disorders: Osteoporosis: Assess fracture risk in patients using bone mineal density and risk factors.
	 epilepsy. Describe the classification of different seizure types. Conduct initial assessment of patients newly diagnosed with epilepsy. Apply the general principles of antiepileptic drug therapy in the follow-up assessment of patients with epilepsy. Drug management of psychiatric disorders: Depression: Describe the disease burden, epidemiology, diagnosis, prognosis, and management of major depressive disorder and other depressive disorders. Conduct initial assessment of patients who present with new diagnosis of depression or who are suspected of having depression but have not been formally diagnosed. Outline monitoring parameters and follow-up plans for patients using pharmacological therapy to manage their depression. Provide guidance to patients on how to manage partial/non-response or adverse effects of medications. Drug management of bone and joint disorders: Osteoporosis: Assess fracture risk in patients using bone mineal density and risk factors. Identify potential complications from osteoporosis drug therapy.

	Rheumatoid Arthritis:	
	• Describe the epidemiology, etiology, clinical presentation, and diagnosis of	
	rheumatoid arthritis.	
	• Describe the goals of therapy and the management strategy for	
	rheumatoid arthritis.	
	Conduct an initial assessment of a patient newly diagnosed with	
	rheumatoid arthritis.	
	• Conduct a follow-up assessment of a patient on disease-modifying ant	
	rheumatic drug therapy, considering the regimen's effectiveness and	
	safety and the patient's ability to adhere	
Session 24 (Week 24)	Drug management of infectious diseases:	
5C351011 24 (WCCR 24)	• Describe the core elements of approach to infectious disease assessment.	
	Describe the use of empiric, definitive, and prophylactic antimicrobial therapies	
	therapies.	
	Describe the use of an antibiogram.	
	Describe the approach to interpretation of culture results.	
Session 25 (Week 25)	CNS infection:	
	 Pathophysiology of CNS infections ⊗ 	
	 Most common pathogens & risk factors 	
	Antibiotic selection issues	
	 Appropriate empirical antimicrobial regimens 	
	Prevention strategies	
	Adjunctive therapy	
	Components of monitoring plan	
Session 26 (Week 26)	Oncology:	
· · · ·	 Pathophysiology, Type of cancer and risk factors 	
	Diagnosis and staging of tumor cancer	
	Clinical presentation and Complications of Malignancy	
	• Oncology management. Combination chemotherapy, Adjuvant	
	Chemotherapy, Neoadjuvant chemotherapy.	
	Complication of cancer chemotherapy.	
Session 27 (Week 27)	Leukemia and Lymphoma:	
JESSION 27 (WEEK 27)		
	 Types and symptoms Bick factors and diagnostic methods 	
	Risk factors and diagnostic methods,	
	 Management of therapy, 	
	Chronic Non concor pain:	
	Chronic Non-cancer pain:	
	 To identify key features of chronic non-cancer pain as a pathological form of pain 	
	of pain	
	• To review assessment strategies that allow the clinical pharmacist to	
	assess pain and evidence of reduced coping in chronic pain Patients.	
	To link pain and coping assessments to pharmacotherapy optimization and management	
	management	
Session 28 (Week 28)	Drug management of anemia:	
	Describe the classification of anemia.	
	Complete a patient assessment and interpret laboratory findings to	
	determine the most likely cause of anemia.	
	• Apply a monitoring and follow-up plan for patients initiated on treatment	
	for anemia.	

	Final theoretical Exam		
	Practical Part:		
	Clinical pharmacy Clerkship:		
	the fundamental goal of the clinical pharmacy clerkship is to provide a		
	structured, practical and closely supervised professional experience that enables the students to better assume their future role as a competent clinical		
	pharmacist. This goal includes the development of professional judgment,		
	pharmaceutical care practice competencies and technical skills.		
	At the completion of clerkship, the students should be able to demonstrate		
	competencies in the following areas		
	\succ To obtain accurate medication histories & gather other relevant patient's		
	data.		
	To learn medical terminologies commonly used by health care professionals		
	in the patient care areas.		
	To learn interpretation of common clinical laboratory tests.		
	To perform effective drug regimen reviews and identify actual and potential medication – related problems.		
	 To develop a pharmaceutical care plan for the patient. 		
	 To recommend a therapeutic drug monitoring plan, including drug 		
	concentration monitoring and indicators of efficacy and toxicity.		
	> To assess drug therapy regimen in a patient with alter renal or hepatic		
	function.		
Practical Part:	> To demonstrate an awareness of the assessment skills in areas necessary to		
	monitor medication outcomes.		
	Communicate effectively with health care professionals and others both		
	orally and in		
	To perform complete and accurate patient counseling and enhance patient education and compliance.		
	 To provide drug information to health care professionals and 		
	patients and to demonstrate competencies in the following areas:		
	 Indication – specific prescribing practice 		
	Appropriate drug dosage selection		
	 Appropriate dosage – form selection 		
	Drug use in pregnancy		
	Drug use in pediatrics		
	Drug use in geriatrics		
	Dosage adjustment in renal impairment		
	 Dosage adjustment in hepatic impairment Management of drug interactions 		
	 Detection & management of adverse reaction & drug induced 		
	diseases.		
	 To demonstrate professional attitude, motivation and ethics. 		
	 To demonstrate the fundamental knowledge of pharmacotherapeutics 		
	in the areas necessary to provide the service.		
	> To provide the student opportunities to engage in scholarly activities (i.e,		
	special projects, presentations, research activities).		
	Final Practical Exam		
Attendance	Students are expected to attend every session of class, arriving on time,		
Expectations	returning from breaks promptly and remaining until class is dismissed. Absences		
	are permitted only for medical reasons and must be supported with a doctor's		

	note.	
Generic Skills	The faculty is committed to ensuring that students have the full range of knowledge and skills required for full participation in all aspects of their lives, including skills enabling them to be life-long learners. To ensure graduates have this preparation, such generic skills as literacy and numeric, computer, interpersonal communications, and critical thinking skills will be embedded in all courses.	
Course Change	Information contained in this course outline is correct at the time of publication. Content of the courses is revised on an ongoing basis to ensure relevance to changing educational employment and marketing needs. The instructor will endeavor to provide notice of changes to students as soon as possible. Timetable may also be revised.	
	Description / routine activities of students during the clerkship	
	 Description / routine activities of students during the clerkship Student will perform the following activities during clerkship rotations: Taking history from the patient with special emphasis on medication history. Participation in Medical Rounds to learn how health care professionals; Assess/ identify patient's disease and medication related problems Treat/ resolve actual disease and medication related problems Prevent potential disease and medication related problem Learning medical terminologies commonly used by health care professionals in patient- care areas. Developing written and oral communication skills i.e. how to communicate effectively with health care professionals and others, both orally and in writing. Monitoring patient compliance statue & adherence to drug therapy and to identify the factors responsible for non-compliance. Patient education and counseling to improve compliance during patient stay at the hospital and at the time of discharge. Reviewing patient medication related problems. Untreated conditions(s) Improper drug selection/ taking wrong drug Sub therapeutic dose Excessive dose Improper drug selection/ taking wrong drug Sub therapeutic dose Excessive dose Requiring dose adjustment in renal impairment. Requiring dose adjustment in hepatic impairment Therapeutic duplication Pregnancy/lactation related problems. 	
	• Non-compliance	
	 Use of narrow therapeutic index drug(s) without monitoring Poly-pharmacy 	
	 Poly-pharmacy 	

 Cost related problems
 Miscellaneous medication related problems
 Developing pharmaceutical care plan for the patient.
 Learning how to provide Drug information to the patients and health care professionals.
• Any other activity which the supervisor considers necessary to be performed by the students.

Hospital pharmacy

1	Course name	Hospital pharmacy
2	Course Code	РН308
3	Course type: /general/specialty/optional	Specialty
4	Accredited units	3 units (2 hr. lecture, 1 lab /week)
5	Educational hours	4 hrs/week
6	Pre-requisite requirements	Pharmacology I,II and pharmaceutics
7	Program offered the course	Bachelor Degree in Pharmaceutical Sciences
8	Instruction Language	English Language
9	Date of course approval	12/2021

Brief Description:	Teaching of the syllabus will be in acco	ordance with current Libyan regulation	
bhei Description.	and WHO proposals.	Stuance with current Libyan regulation	
	This course will provide students with a fundamental understanding of the		
	national and international legislation and law in pharmacy. activities of the		
	pharmacist. Good Storage Practice. Classifications of hospitals, its function		
	and pharmacy department. Drug information center. Large volume		
	medications and principles of radio pharmaceutics and		
	radiopharmaceuticals. As well as the use of nuclear radiation in the		
	management of some disease.		
Textbooks required	1. Modern dispensing and hospital pharmacy. N K Jain, G D Gupta 2018		
for this Course:	2. Hospital pharmacy sciences		
	 Aulton's pharmaceutics Sciences direct website 		
	5. Additional Resources: Lectures No	otes	
Course Duration	24 weeks		
Delivery	Lectures (Tools: board, data show, vid	eo).	
	Practical classes (Lab experiments+ pr		
	saline, evaluation of prescription form	,	
Course Objectives:	At the end of the course students will	be able to:	
	- Explain local and international legalization in the field of pharmacy.		
	- Describe the organization structure c		
	- Understand the manufacturing practice of various large volume		
	medications Understand the admixtures and incompatibilities of medications.		
	- Describe the management of inventory control in the hospital pharmacy.		
	- Classify the radioactive materials and	d understanding their clinical uses .	
Course Assessments	Midyear exam	20%	
	Quizzes, reports, presentation	10%	
	Practical continuous assessment,	10%	
	exam	2021	
	Final Practical exam	20%	
	Final theoretical exam 40%		
Content Breakdown	Total 100%		
Topical Coverage	Content Breakdown Topical Coverage		
Session 1 (Week 1)	Unit I: Outlines of pharmacy legislation including Local regulations. (4 hr.)		
Session 2 (Week 2)	Outlines of pharmacy legislation including Local regulations.		
Session 3 (Week 3)	Unit II: Pharmacy as a system in healt	th –care delivery. (8 hr.)	
	- Introduction.	ivition of the pharmanisty. The	
	procedure for procurement &	ivities of the pharmacist: - The warehousing of drugs and	
	pharmaceuticals in the hospita		
Session 4 (Week 4)	-The scope of pharmacy & activities of the pharmacist: - The		
	responsibility of the hospital pharmacist.		

	- Different methods of drug distribution systems in hospitals.	
	- The procedure for Distribution of Narcotic and other controlled	
	substances	
Session 5 (Week 5)	-The scope of pharmacy & activities of the pharmacist.	
	- Hospital pharmacist's participation in continuing education	
	programme.	
	 inventory control, methods and types of inventory control. 	
Session 6 (Week 6)	- Pharmacy as a profession.	
Session 7 (Week 7)	Unit III: Storage of medical products. (5 hr.) including:	
	 outlines of Good Storage Practice (GSP). 	
Session 8 (Week 8)	- Outlines of Good Storage Practice (GSP).	
Session 9 (Week 9)	- Outlines of Good Storage Practice (GSP).	
•••••	Unite IV: Hospital and it organization: (7 hr.)	
	 The hospital and its requirements. 	
Session 10 (Week 10)	- Classifications of hospitals.	
	- Functions of hospitals.	
	- The hospital pharmacy department.	

Session 11 (Week 11)		
Session 12 (Week 12)	Midyear exam	
Session 13 (Week 13)		
Session 14 (Week 14)		
Session 15 (Week 15)	- The practices of hospital pharmacist in hospital.	
Session 16 (Week 16)	- Location, facilities and personal.	
	- The pharmacy and therapeutic committee.	
Session 17 (Week 17)	Unit VI: Drug information center (DIC): (6 hr.)	
	- Primary source of informations.	
	- Secondary source of informations.	
	- Tertiary source of informations.	
Session 18 (Week 18)	- Guidelines to establish (DIC) in hospitals.	
	- Services offered by DIC.	
Session 19 (Week 19)	- Common faults in advising patients.	
	- The hospital formulary.	
Session 20 (Week 20)	Unit VII: In-patient pharmacy service: (6 +2hr.)	
	- Fluid and electrolyte therapy.	
Session 21 (Week 21)	- Fluid and electrolyte therapy.	
Session 22(Week 22)	- Fluid and electrolyte therapy.	
	- Parenteral nutrition.	
Session 23 (Week 23)	Unit VIII: Parenteral admixtures and incompatibilities.(3 hr)	
Session 24 (Week 24)	Unit IX: Methods of I.V administration and sets including flow rates, &	
	flow control. (5 hr.)	
Session 25 (Week 25)	- Methods of I.V administration and sets including flow rates, & flow	
	control.	

Session 26 (Week 26)	Unit X: Radio pharmacy: (6 hr.)	
	- Introduction.	
	- importance of radiopharmaceuticals, frequently used radio	
	pharmaceuticals in the hospital.	
Session 27 (Week 27)	- Therapeutic and diagnostic radio-pharmaceuticals in pharmacy	
Session 28 (Week 28)	 The method for handling radiopharmaceuticals in hospital. Radio-pharmaceutical quality control. 	
	Final theoretical exam	
Practical work	 Part II: Practical in Hospital Pharmacy: (One lab/ week) 1) Test for pyrogens on water for injection. 2) Evaluation of the plastic transfusion bottles used for large volume parenterals. 3) Operation of the sterilization equipment (Autoclave). 4) Test for hydrolytic resistance of glass containers used for parenterals. 5) Evaluation of prescription form. 6) Preparation and sterilization of normal saline IP. 7) Preparation and sterilization of dextrose injection IP. 8) Study of drug profile of radiopharmaceuticals. 9) Study of poisons information service. 	
	10) Study of drug information service.11.Final practical Exam	
Attendance Expectations	Students are expected to attend every session of class, arriving on time, returning from breaks promptly and remaining until class is dismissed. Absences are permitted only for medical reasons and must be supported with a doctor's note.	
Generic Skills	The faculty is committed to ensuring that students have the full range of knowledge and skills required for full participation in all aspects of their lives, including skills enabling them to be life-long learners. To ensure graduates have this preparation, such generic skills as literacy and numeric, computer, interpersonal communications, and critical thinking skills will be embedded in all courses.	
Course Change	Information contained in this course outline is correct at the time of publication. Content of the courses is revised on an ongoing basis to ensure relevance to changing educational employment and marketing needs. The instructor will endeavor to provide notice of changes to students as soon as possible. Timetable may also be revised.	

Pharmacy practice

1	Course name	Pharmacy Practice
2	Course Code	РН 407
3	Course type: /general/specialty/optional	Specialty
4	Accredited units	3 Units (Theoretical 2 Lecture/Week Practical 2 hours/Week)
5	Educational hours	4 hr/week
6	Pre-requisite requirements	Pharmaceutics I, II and Pharmacology I, II
7	The program offered the course	Department of Pharmaceutical care
8	Instruction Language	English
9	Date of course approval	12/2021

Course Assessments	Midyear exam	20%
	Quizzes, reports, presentation	10%
	Practical continuous assessment, exam	10%
	Final Practical exam	20%
	Final theoretical exam	40%
	Total	100%
Content Breakdown	Content Breakdown Topical Coverage	
Topical Coverage		
Session 1 (Week 1)	Unit I: Pharmaceutical care: 8 hr.	. But we
	Introduction to Pharmac	
		the scope of Pharmacy Practice
	 Essential components of 	pharmaceutical care
	Drug related problems.	
		f pharmacy to drug related problems.
	• Exploration of the drug process.	
	Clinical skills and Pharmacist's ro	ble in pharmaceutical care.
Session 2 (Week 2)	The development of the concept of pharmaceutical care.	
	• The pharmacist's functions.	
	Functions related to the individu	al patient.
	Functions related to the community.	
Session 3 (Week 3)	The Pharmacist's Working up of Drug Therapy (The PWDT process)	
	• • •	tient past medical history, patient family
	history, patient social history, patient social history, patient finding, laboratory and test resul	atient history of present illness, physical
	inding, laboratory and test resul	15.
Session 4 (Week 4)	 Clinical Skills and Pharmacist's ro 	le in pharmaceutical care
	 Pharmaceutical car as the model 	
Session 5 (Week 5)	Unit II: Therapeutic Plan 8 h	r.
	The CORE pharmacotherapy plan	
	The CORE pharmacotherapy prol	blems.
	The FARM progress note	
Session 6 (Week 6)	Patient's factor's in drug-product select	ion: Isibility and role in drug product
	selection	isibility and role in drug product
		roduct coloction
	Factors affecting drug-pl Dationt accontance consideration	
	 Patient acceptance consideration Patient age consideration 	1.
	Environmental consideration	
Session 7 (Week 7)	Disease state consideration	
(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Patient compliance	

	Biopharmaceutical consideration	
Session 8 (Week 8)	Performance of drugs in clinical practice and factories effects their	
	methods of presentation	
	 Concept of optimized drug products and controlled release delivery 	
	systems (CR-DDS)	
	1. Definitions	
	2.Optimized controlled release (CR) products	
	3. Advantages of sustained /controlled drug therapy	
	4.Categories of non-immediate delivery systems	
	5. Types of CR-DDS (examples)	
Session 9 (Week 9)	Unit III: Drug supply (6 hours)	
Session 9 (week 9)	• The goal of drug supply (6 hours)	
	The goal of drug supply The drug supply process	
Session 10 (Week 10)	 Problems in the drug supply process 	
Session 11 (Week 11)	Midyear Exam	
Session 12 (Week 12)		
Session 13 (Week 13)		
Session 14 (Week 14)		
Session 15 (Week 15)	Improving drug supply	
	The dimensions of drug supply	
Session 16 (Meak 16)	Unit N/Decrearding to sumptome in phermony practice through OTC and	
Session 16 (Week 16)	Unit IV:Responding to symptoms in pharmacy practice through OTC and counseling:	
	 Responding to symptoms in Pharmacy Practice 10 hours) 	
	The Communication Process	
	1. The goal of effective communications	
	2. The scope of medication-counseling sessions	
	a) In organized health care setting	
	b) In the community setting	
	3. Patient assessment and consultation self-medication	
	a) Importance of communication skills.	
	b) Provision of pharmaceutical care through	
	Patient-Pharmacist communication process	
Session 17 (Week 17)	Non-Prescription medications (OTC medications)	
	OTC criteria according to international stranded	
	 Label requirements for non-prescription medicine Non-prescription medication as a primary therapy and related conditions 	
	• Non-prescription medication as a primary therapy and related conditions a) Antidiarrheal and other gastrointestinal products	
	b) Laxative products	
	c) Antacids and other gastrointestinal reflux disease products	
Session 18 (Week 18)	d) Cold and Allergy product	
	e) Internal analgesics (management of headache, pain and fever)	

	f) Menstrual products	
	g) Acne Products	
	h) Others	
Session 19 (Week 19)	In-home monitoring devices	
. ,	4- In-Home testing and monitoring devices	
	a) Diabetes care products and monitoring kits	
	b) Pregnancy testing and ovulation prediction testing kits	
	c) Fecal occult blood kits	
Session 20 (Week 20)	d) Cholesterol monitoring kit	
	e) Home blood pressure and temperature monitoring	
	f) Home respiratory devices	
Session 21 (Week 21)	Unit V: Dispensing prescriptions2 hr.	
Session 22 (Week 22)	Unit VI: Mathematical principles of drug therapy 2 hr.	
Session 23 (Week 23)	Unit VII: Pharmacy system 6 hr.	
Session 24 (Week 24)	Pharmacy system	
Session 25 (Week 25)	Pharmacy and therapeutic committee	
	Organization, functions, Policies of the pharmacy and therapeutic committee in	
	including drugs into formulary, inpatient and outpatient prescription, automatic	
	stop	
Session 26 (Mask 26)	order, and emergency drug list preparation.	
Session26 (Week 26) Session 27 (Week 27	Unit VIII: Pharmacy information and research 4 hr.	
Session 28 (Week 28)	Pharmacy information and research	
JESSION 20 (WCCK 20)	Pharmacy information and research	
Practical Work	Final theoretical exam	
	One lab per week: N.B. Practical sessions are illustrating the theoretical concepts of the above	
	N.B. Fractical sessions are indstrating the theoretical concepts of the above	
	Final practical exam	
Attendance	Students are expected to attend every session of class, arriving on time.	
Expectations	Absences are permitted only for medical reasons and must be supported with a	
Expectations	Absences are permitted only for medical reasons and must be supported with a doctor's note.	
	doctor's note.	
Expectations Generic Skills	doctor's note. Independent learning, critical thinking, and problem solving.	
•	doctor's note. Independent learning, critical thinking, and problem solving. Basic IT and presentation skills.	
•	doctor's note. Independent learning, critical thinking, and problem solving. Basic IT and presentation skills. Integration of different fields of knowledge.	
•	doctor's note. Independent learning, critical thinking, and problem solving. Basic IT and presentation skills.	
Generic Skills	doctor's note. Independent learning, critical thinking, and problem solving. Basic IT and presentation skills. Integration of different fields of knowledge. Team working. Communication skills.	
	doctor's note.Independent learning, critical thinking, and problem solving.Basic IT and presentation skills.Integration of different fields of knowledge.Team working.Communication skills.The details of course contents are updated according to the outcomes of new	
Generic Skills	doctor's note.Independent learning, critical thinking, and problem solving.Basic IT and presentation skills.Integration of different fields of knowledge.Team working.Communication skills.The details of course contents are updated according to the outcomes of newresearch and published paper. Content of the courses is revised on an ongoing	
Generic Skills	doctor's note.Independent learning, critical thinking, and problem solving.Basic IT and presentation skills.Integration of different fields of knowledge.Team working.Communication skills.The details of course contents are updated according to the outcomes of newresearch and published paper. Content of the courses is revised on an ongoingbasis to ensure that the course fit the graduation competences and community	
Generic Skills	doctor's note.Independent learning, critical thinking, and problem solving.Basic IT and presentation skills.Integration of different fields of knowledge.Team working.Communication skills.The details of course contents are updated according to the outcomes of newresearch and published paper. Content of the courses is revised on an ongoing	

Pathology

	~	
I	Course name	Pathology
2	Course Code	PH 206
3	Course type:	
	/general/specialty/optional	General
	/general/specialty/optional	
4	Accredited units	
-		3 units (2 hours theory and 1 lab /week)
5	Educational hours	
-		4 hours/week
6	Pre-requisite requirements	
-	The requirements	Physiology
7	Program offered the course	
	rogram onered the course	Department of pharmaceutical care
8	Instruction Language	
0	Instruction Danguage	English
9	Date of course approval	12/2021

	T I D (1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Brief Description: Textbooks required for this Course:	The Pathology module is divided into two parts- general pathology and systemic pathology. It is designed to cover the following topics: cellular injury and adaptation, acute and chronic inflammation, regeneration and repair, circular disturbance, disturbances of cell growth. The students also study in this subject the Pathology of the immune reaction, bacterial and protozoal diseases, tumor pathology and endocrine CVS, GIT, respiratory and urinary system diseases. 1. Textbook: Pathology and therapeutics for Pharmacists: Green & Harris, Pharmaceutical Press. 2. Rubin's Pathology, Clinicopathologic Foundations of Medicine, 6th edition 2011 edited by Rubin, Strayer, and Rubin (Lippincott Williams and	
	Wilkins).	
Course Duration	28 weeks	
Delivery	 Lecture-based, Group interaction and discussion, Use of video technique, practical classes. 	
Course Objectives:	-	ere for the students to understand the
	etiology, pathogenesis and key morphological and clinical features of major disease conditions, as well as to correlate these with the fundamental principles of therapy.	
Course Assessments	Midyear exam	20%
	Quizzes, reports, presentation	10%
	Practical continuous assessment, exam	10%
	Final Practical exam	20%
	Final theoretical exam	40%
	Total	100%
Content Breakdown	Content Breakdown Topical Covera	ge
Topical Coverage		
Session 1(Week 1)	General Pathology:	
	Unit I: Cellular response to injury:	
	Causes of cell injury.	
	Mechanism of cell injury.	
	Morphological alteration in ce	ell injury. eath): Coagulative, Gaseous necrosis,
	 Necrosis (pathological cell s de liquifactive, fat, Zenker's necro 	
	Apoptosis.	
	Gangrene	
Session 2 (Week 2)	Unit II: Intracellular accumulation and	d Extracellular depositions:
	Intracellular accumulation:	
	Steatosis (fatty change)	
	Cholesterol and cholesterol es Evtracellular denositions:	sters
	 Extracellular depositions: Pathological calcification 	
	Amyloidois	
Session 3 (Week 3)	Unit III: Cellular adaptations/ growth disturbances.	
Session 4 (Week 4)	Unit IV: inflammation	
. ,	Acute inflammation :	
	N	

	Definition	
	 local signs and symptoms, systemic effects 	
	 outcomes of acute inflammation 	
	 types acute inflammation 	
	 abscess, furuncle, carbuncle, 	
	 serous inflammation, fibrinous inflammation 	
	 chemical mediators and regulators of inflammation 	
Session 5 (Week 5)	Chronic inflammation, repair and cell injury:	
Session 5 (Week 5)	Definition	
	 Cells of chronic inflammation, 	
	Types of chronic inflammation, granuloma,	
	Healing and repair	
Session 6 (Week 6)	Unit V: Regeneration and repair :	
	Healing of wounds:	
	a) Primary and secondary types,	
	b) Factors affecting wound healing.	
Session 7 (Week 7)	Unit V: circulatory disturbances:	
	 Edema: definition, types, pathogenesis. 	
	Embolism: definition, types.	
	 Infarction: definition, types. 	
	 Hemorrhage and shock: mechanism and types. 	
	Congestion: active and passive.	
Session 8 (Week 8)	Unit VI: Disturbances of cell growth:	
	Aplasia - Hypoplasia Hyperplasia Atrophy Hypertrophy.	
	Hematoma Metaplasia Anaplasia.	
Session 9 (Week 9)	Unit VII: General tumor pathology:	
Session J (Week J)	a) Neoplasia (tumors)	
	Definition, classification, differences between benign and malignant tumors,	
	types of benign and malignant tumors, malignancies of hematopoietic cells	
	(Leukemia) and lymphomas.	
Session 10 (Week 10)	b) Carcinogenesis:	
Session 10 (Week 10)	Clinical aspects of tumors, diagnosis of cancer, cancer arraigning and	
	staging.	
Section 11 (Week 11)	заднь.	
Session 11 (Week 11)		
Session 12 (Week 12)	Midterm exam	
Session 13 (Week 13)		
Session 14 (Week 14)		
Session 16 (Week 15)	Unit VIII: Pathology of the immune reaction:	
	Introduction to the immune system.	
	Cells and other elements involved in the immune response (T,Bcells)	
	Hypersensitivity reactions; types (I, II,III, IV).	
Session 17 (Week 16)	HLA system.	
	Transplant pathology.	
	Auto-immune diseases:Types, etiology, pathogenesis, clinical features,	
	pathology and prognosis of selected major illness (SLE, Scleroderma).	
	Acquired immune deficiency syndromes.	
Session 18 (Week 17)	Unit IX: Infections:	
	a) Tuberculosis:	

	incidence, pathogenesis, primary complex secondary TB and features of pulmonary TB.	
Session 19 (Week 18)	b) Syphilis: Mode of transmission, stages, signs and symptoms, organs involved and	
	effects. Congenital syphilis. c) Gonorrhea:	
	Unit X: Protozoal and Helminithic diseases:	
Session 20 (Week 20)	Amoebiasis, Leishmaniasis, Hydatid disease. Malaria.	
Session 20 (Week 20)	Bilharzisis: Geographical distribution, types, and complications.	
Session 21 (Week 21)	Systemic pathology:	
· · · ·	Unit XI: Cardiovascular system:	
	Atherosclerosis- pathogenesis, risk factors, complications.	
	Hypertension.	
	Ischemic heart disease (IHD)- types of angina pectoris, rheumatic heart	
	disease.	
	linfective endocarditis.	
Session 22 (Week 22)	Unit XII: Respiratory system:	
	Tonsillitis, bronchitis, bronchial asthma, pneumonia- bronchiectasis- Bronchogenic carcinoma.	
Session 23 (Week 23)		
Session 25 (Week 25)	Unit XIII: Gastro-intestinal system: Gastritis-Peptic Ulcer, Ulcerative colitis, Crohn's disease, Zollinger- Ellison	
	syndrome, Pancreatitis	
Session 24 (Week 24)	Unit XIV: Biliary system and liver:	
~	Cholecystitis- Hepatitis- Cirrhosis- complications.	
Session 25 (Week 25)	Unit XV: Urinary system:	
	Glomerulonephritis: definition, types.	
	Drug-nephritic syndrome-induced tubule- cystitis – interstitial nephritis-	
	pyelonephritis.	
Session 26 (Week 26)	Unit XVI: Endocrine system:	
	Thyroid: hypethyroidism, hypothyroidism goiter, pyelonephritis-diabetes	
	mellitus, types, complications Adrenal glands.	
Session 27 (Week 27)		
Session 27 (Week 27)	Unit XVII: Hematopoietic system: Classification of anaemias- Iron deficiency anemia – Vitamin B12 and folate	
	deficiency anaemia- aplastic anaemia- thrombocytopenia- leucopenia.	
Session 28 (Week 28)	Unit XVIII: Genetic mechanism of diseases:	
((, com 2 0)	Structure of the genom and its disorders, selected definitions, mutationof	
	genes, mendelian disorders, normal karyo type, cytogenetic disorders, role	
	of moleuclar diagnostics.	
	Final theoretical Exam.	
Practical work	Practical Part:	
(one/week)	List of Museum specimens:	
	1. Fibrinous pericarditis, Diphtheria lf larynx, Brain abscess, acute	
	appendicitis	
	2. Infarction of spleen, CVC liver, Cerebral hemorrhage.	
	3. Adenoma thyroid, Fibroadenoma Breast (Carcinoma stomach, Carcinoma Ureter).	
	4. Lipoma (Leiomyoma Uterus, Metastasis Lung, Malignant Melanoma skin).	

	 Miliary Tuberculosis, lung (Tuberculosis lymphadenitis, Gumma liver- Bilharzial Hepatic fibrosis- Tuberculosis small intestine- Hydatid cyst liver, Amebic liver abscess). Acute bacterial endocarditis (recent infection heat, Atheresclerosis, Lobar pneumonia, Bronchogenic carcinoma. Crohn's disease, Ulcerative colitis-Micro-nodular cirrhosis- Macro-nodular cirrhosis- Chronic cholecystitis- Chronic gastric ulcer. Acute pyelonephritis, Acute cystitis, Goiter. 	
	Final Practical Exam	
Attendance Expectations	Students are expected to attend every session of class, arriving on time, returning from breaks promptly and remaining until class is dismissed. Absences are permitted only for medical reasons and must be supported with a doctor's note.	
Generic Skills	The faculty is committed to ensuring that students have the full range of knowledge and skills required for full participation in all aspects of their lives, including skills enabling them to be life-long learners. To ensure graduates have this preparation, such generic skills as literacy and numeric, computer, interpersonal communications, and critical thinking skills will be embedded in all courses.	